New combo therapy aims to tame rare blood vessel disease
NCT ID NCT05329090
First seen Jun 13, 2026 · Last updated Jun 22, 2026 · Updated 2 times
Summary
This study tested whether adding rituximab to standard steroid treatment helps adults with IgA vasculitis—a disease causing inflammation in small blood vessels—achieve remission without needing long-term steroids. The trial enrolled 75 adults with newly diagnosed or relapsing disease affecting organs like the kidneys or gut. Participants received either rituximab or a placebo, plus steroids, and were followed for up to a year to see if they could stop steroids while staying in remission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA VASCULITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
APHM de La Timone
Marseille, 13385, France
-
CHRU Bretonneau
Tours, 37044, France
-
CHU Clermont Ferrand
Clermont-Ferrand, 63000, France
-
CHU Clermont Ferrand
Clermont-Ferrand, 63003, France
-
CHU Marseille
Marseille, 13005, France
-
CHU Nantes
Nantes, 44093, France
-
CHU Nîmes (Caremeau)
Nîmes, 30029, France
-
CHU Strasbourg
Strasbourg, 67091, France
-
CHU Toulouse
Toulouse, 31059, France
-
Hopital La Cavale Blanche
Brest, 29200, France
-
Hôpital André Grégoire
Montreuil, 93100, France
-
Hôpital Cochin
Paris, 75679, France
-
Hôpital Edouard Herriot
Lyon, 69003, France
-
Hôpital Foch
Suresnes, 92150, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rituximab (a drug that depletes certain immune cells) plus glucocorticoids (steroids)
What this could lead to
If successful, this could offer a more effective treatment for IgA vasculitis, reducing the need for long-term steroids and their side effects.
What could go wrong
This is a relatively small phase 3 trial (75 people), and rituximab may not work better than steroids alone. It also carries risks like infusion reactions and increased infection risk.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.